December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this phase III study in patients with newly diagnosed advanced myeloproliferative CMML comparing decitabine vs hydroxyurea no differences in EFS, OS, or transformation to AML were reported.